Skye Bioscience, Inc. SKYE 深 沪
已收盘 01-30 16:00:00 美东时间
1.01
+0.050
+5.21%
华盛通- 最 高1.0232
- 今 开0.958
- 成交量 20.22万股
- 最 低 0.94
- 昨 收 0.96
- 总市值 3129.83万
- 52周最高 5.75
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.6844
- 委 比 62.78%
- 总股本 3098.84万
- 历史最高 17.6473
- 量 比 1.43
- 振 幅 8.67%
- 历史最低 0.6844
- 每 手 1
- 风险率 1.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Skye Bioscience Presents Nimacimab-Tirzepatide Data At Keystone Obesity Therapeutics Conference
Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye") a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled
01-29 20:14
Skye Bioscience Issues 2026 Corporate Outlook Outlining Planned Clinical, Manufacturing, And Corporate Milestones To Advance Nimacimab, Skye's Peripherally Restricted CB1-Inhibiting Antibody
CBeyondTM Phase 2a 26-week extension data update and interim results expected Q1 2026.CBeyond Phase 2a Data Monitoring Committee (DMC) meeting on December 14, 2025, continued to demonstrate favorable safety
01-12 20:59
Skye Bioscience Announced Non-Exclusive License Agreement For Halozyme Therapeutics' Enhanze Drug Delivery Technology For The Development And Potential Commercialization Of A Subcutaneous Formulation Of Nimacimab For Obesity
Skye will make milestone payments tied to the achievement of certain development and commercialization events. Halozyme will also be entitled to mid-single digit royalties on net sales of nimacimab developed with ENHANZE
01-05 20:16
Skye Bioscience Enters Non-Exclusive Licensing And Collaboration Agreement With Halozyme For Subcutaneous Nimacimab Using ENHANZE Technology
On December 18, 2025, Skye Bioscience, Inc. (the "Company") entered into a Non-exclusive Collaboration and License Agreement (the "Agreement") with Halozyme, Inc. ("Halozyme"). Under the terms of the Agreement,
2025-12-24 05:08
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
Skye Bioscience To Highlight Recent Topline Data From CBeyond, Phase 2 Proof-Of-Concept Study Of Nimacimab, Skye's Peripherally-Restricted CB1 Inhibitor Antibody, At ObesityWeek 2025
Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will present a
2025-11-05 20:28
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gain...
2025-10-07 01:09
US Stocks Mixed; Dow Falls 100 Points
U.S. stocks traded mixed this morning, with the Dow Jones index falling more th...
2025-10-06 23:05
Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial
Skye Bioscience announced topline results from its Phase 2a CBeyond™ study of nimacimab, a CB1 inhibitor. Nimacimab monotherapy did not meet its primary weight loss endpoint, likely due to suboptimal drug exposure. However, when combined with semaglutide, nimacimab demonstrated clinically meaningful additional weight loss compared to semaglutide alone. The combination showed a favorable safety profile with no increase in gastrointestinal or neuro...
2025-10-06 11:00
